New Treatments Developed in Open Innovation Program
The University of Cambridge website reported that Cambridge researchers are developing new therapies as part of a collaborative program with industry. Two revolutionary treatments which could alleviate pain in people with hypersensitivity to heat, and provide a new regenerative therapy with MS sufferers, are being developed by University of Cambridge
Comments Off on New Treatments Developed in Open Innovation Program • Read this story »
More Articles
Babraham, AZ and Pfizer in Open Innovation Alliance
BusinessWeekly reports that three Cambridge UK biomed technology powerhouses have reaffirmed their commitment to the open innovation agenda through a new initiative at the heart of the Cambridge cluster. The new collaboration aims to identify new therapeutic treatments, with the premise that early-stage
Comments Off on Babraham, AZ and Pfizer in Open Innovation Alliance • Read this story »
Cambridge U. Begins New Collaboration with GSK
The InPharm website announced that the University of Cambridge has begun a new collaboration with GlaxoSmithKline. The collaboration will see researchers from both sides working together at the Stevenage Bioscience Catalyst, the UK’s first open innovation bioscience campus. “A key element of
How to make open innovation work in Europe
The Science|Business website reports that the academic ‘father’of open innovation, Henry Chesbrough, is launching a European forum for it, in collaboration with the Science|Business Innovation Board. Chesbrough discusses the European challenges in an interview with the Science|Business
How Cambridge academics are learning open innovation
The Openinnovationblog notes that many large corporations talk of transforming themselves to embrace open innovation, and opening up to external ideas. But grand strategic statements and new corporate PowerPoint slides do not change the capabilities of an organization. The blog goes on to discuss
Cambridge partners with Lilly in Open Innovation Drug Discovery Platform
The Cambridge Interprise website reports that the University of Cambridge is partnering with global pharmaceutical company Eli Lilly and Company in an active collaboration programme helping to find and develop potential new medicines, particularly in the areas of greatest need. Over 60 European institutions